» Articles » PMID: 15789367

Statins and Hepatotoxicity: Focus on Patients with Fatty Liver

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2005 Mar 25
PMID 15789367
Citations 72
Authors
Affiliations
Soon will be listed here.
Citing Articles

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis.

Jiang Y, Wang Y, Ma S, Qian L, Jing Y, Chen X Front Cardiovasc Med. 2025; 11:1415668.

PMID: 39975967 PMC: 11836037. DOI: 10.3389/fcvm.2024.1415668.


Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review.

Alqahtani M, Alzibali K, Mahdi A, Alharbi O, Harbi R, Alkhaldi H Cureus. 2024; 16(7):e65202.

PMID: 39176329 PMC: 11340782. DOI: 10.7759/cureus.65202.


Genetically mimicked effects of ASGR1 inhibitors on all-cause mortality and health outcomes: a drug-target Mendelian randomization study and a phenome-wide association study.

Yang G, Schooling C BMC Med. 2023; 21(1):235.

PMID: 37400795 PMC: 10318778. DOI: 10.1186/s12916-023-02903-w.


Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Xu X, Poulsen K, Wu L, Liu S, Miyata T, Song Q Signal Transduct Target Ther. 2022; 7(1):287.

PMID: 35963848 PMC: 9376100. DOI: 10.1038/s41392-022-01119-3.


KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.

Kang S, Lee H, Yoo J, Cho Y, Kim S, Lee T Clin Mol Hepatol. 2021; 27(3):363-401.

PMID: 34154309 PMC: 8273632. DOI: 10.3350/cmh.2021.0178.